The Tribble with APL: A New Road to Therapy
- PMID: 28486101
- DOI: 10.1016/j.ccell.2017.04.011
The Tribble with APL: A New Road to Therapy
Abstract
The t(15;17) translocation generates a PML-RARα fusion protein causative for acute promyelocytic leukemia (APL). Li et al. now identify the pseudokinase stress protein TRIB3 as an important factor in APL disease progression and therapy resistance. Targeting the interaction of TRIB3 and PML-RARα using peptide technology provides a novel therapeutic approach.
Copyright © 2017 Elsevier Inc. All rights reserved.
Comment on
-
TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.Cancer Cell. 2017 May 8;31(5):697-710.e7. doi: 10.1016/j.ccell.2017.04.006. Cancer Cell. 2017. PMID: 28486108
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
